profit from every $100 of sales.
$0$100
IDEXX Laboratories
$704.23+0.89% today
+0.4% in 1 year
1-year low $504.701-year high $766.68
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $52.37 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What IDEXX Laboratories sold, what it kept, and what it did with the cash.
Sales went from $3.37 billion in 2022 to $4.30 billion in 2025, with $1.06 billion of profit last year.
SalesProfit
IDEXX Laboratories handed back more cash to shareholders than it generated last year.
Buybacks $1.2B
Free cash flow 2025$1.0B
Bought back its own shares$1.2B
Paid as dividends–
Cash vs. debt$180M vs. $976M
IDEXX Laboratories vs. similar companies
IDEXX Laboratories grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| IDEXX Laboratories | 52.4× · Expensive | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.4× · Expensive | ||
 Waters | 140.8× · Very expensive | ||
 WuXi AppTec | 25.8× · Fair price |
AI analysis
An AI analyst reads IDEXX Laboratories's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,707 | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 | |
| 1,571 | 1,889 | 2,004 | 2,190 | 2,379 | 2,660 | |
| 695 | 932 | 899 | 1,097 | 1,128 | 1,360 | |
| 791 | 1,037 | 1,012 | 1,218 | 1,271 | 1,508 | |
| 582 | 745 | 679 | 845 | 888 | 1,059 | |
| 6.71 | 8.60 | 8.03 | 10.06 | 10.67 | 13.08 | |
| 58.0% | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% | |
| 25.7% | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% | |
| 21.5% | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,295 | 2,437 | 2,747 | 3,260 | 3,293 | 3,351 |
| Cash | 384 | 144 | 113 | 454 | 288 | 180 |
| Total debt | – | – | 1,470 | 1,067 | 987 | 976 |
| Total liabilities | 1,662 | 1,747 | 2,138 | 1,775 | 1,698 | 1,745 |
| 632 | 690 | 609 | 1,485 | 1,595 | 1,605 | |
| 87 | 87 | 85 | 84 | 83 | 81 | |
| 86.9% | 106.8% | 34.2% | 34.1% | 34.9% | 41.7% | |
| 92.0% | 107.9% | 111.6% | 56.9% | 55.7% | 66.0% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 648 | 756 | 543 | 907 | 929 | 1,182 | |
| – | – | 159 | 134 | 131 | 138 | |
| – | – | 384 | 773 | 798 | 1,044 | |
| Dividends paid | – | – | – | – | – | – |
| 183 | 747 | 820 | 72 | 837 | 1,217 | |
| 31 | 38 | 50 | 60 | 60 | 60 |
Valuation
- 52.4×
- 48.6×
- 3.67
- 33.2×
- 12.9×
- 53.2×
- 37.3×
- 1.9%
- 1.9%
- 0.0%
Profitability
- 61.8%
- 31.6%
- 24.6%
- 34.2%
- 42.8%
- 37.2%
- 70.9%
- 32.4%
- 67.4%
- 5.8%
Growth
- +9.7%
- +14.3%
- +32.0%
- –
- −1.4%
Financial health
- 0.5×
- 0.61
- 31.9%
- 35.1×
- 1.23
- 0.82
- 1.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 2%of 952
Top 7%of 884
Bottom 21%of 601
Bottom 47%of 886
Top 44%of 987
What analysts expect
- Average price target
- $747.50
- Range
- $640.00 – $800.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 3.47 | 3.41 | +1.8% |
| Feb 2, 2026 | 3.08 | 2.93 | +5.1% |
| Nov 3, 2025 | 3.40 | 3.14 | +8.3% |
| Aug 4, 2025 | 3.63 | 3.28 | +10.7% |
| May 1, 2025 | 2.96 | 2.85 | +3.9% |
| Feb 3, 2025 | 2.62 | 2.39 | +9.6% |
| Oct 31, 2024 | 2.80 | 2.68 | +4.5% |
| Aug 6, 2024 | 3.02 | 2.88 | +4.9% |
News
IDEXX Laboratories, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
75Pass
Benjamin Graham
40No pass
Philip Fisher
79Pass
Peter Lynch
46No pass
Joel Greenblatt
44No pass
Charlie Munger
88Pass
Terry Smith
86Pass
Questions about IDEXX Laboratories
Is IDEXX Laboratories a good stock to buy?
A strong, very profitable business, but the price is high. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the IDEXX Laboratories AI analysis
What does IDEXX Laboratories do?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It is in Diagnostics & Research, based in Westbrook, ME, United States, with 11,000 employees.
Does IDEXX Laboratories pay a dividend?
No. IDEXX Laboratories does not pay a dividend at the moment; in 2025 it returned $1.22 billion to shareholders by buying back its own shares.
Is IDEXX Laboratories stock halal?
Yes. IDEXX Laboratories passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has IDEXX Laboratories stock done over the past year?
Up 0.4% over the past twelve months, to $704.23. It traded between $504.70 and $766.68 and is 8.1% below its high.
Who are IDEXX Laboratories's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with IDEXX Laboratories's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.